Seattle Genetics, Inc. (SGEN)

69.18
1.62 2.29
NASDAQ
Prev Close 70.80
Open 70.95
Day Low/High 68.44 / 72.00
52 Wk Low/High 47.75 / 84.37
Volume 1.81M
Exchange NASDAQ
Shares Outstanding 160.96B
Market Cap 11.40B
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics To Host Conference Call On Positive Topline Results From Pivotal Trial Of Enfortumab Vedotin

Seattle Genetics To Host Conference Call On Positive Topline Results From Pivotal Trial Of Enfortumab Vedotin

Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced...

Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company's antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer...

Seattle Genetics To Present At Cowen And Company 39th Annual Health Care Conference

Seattle Genetics To Present At Cowen And Company 39th Annual Health Care Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.

Seattle Genetics Achieves $30 Million Milestone Payment For European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) In Frontline Hodgkin Lymphoma

Seattle Genetics Achieves $30 Million Milestone Payment For European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) In Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS...

Seattle Genetics Reports Fourth Quarter And Full Year 2018 Financial Results

Seattle Genetics Reports Fourth Quarter And Full Year 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2018.

Seattle Genetics To Present At Guggenheim Healthcare Talks Idea Forum | Oncology Day

Seattle Genetics To Present At Guggenheim Healthcare Talks Idea Forum | Oncology Day

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, DGII, FLWS, JVA, LBRDA, MUR, OLP, RDY, SGEN, TESS, TWIN, VMC, YRCW Downgrades: CRUS, MINI, USLM, ZBH Initiations: CBTX, MBIN, SOGO Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets.

Seattle Genetics Announces Publication Of North American Subgroup Data From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma

Seattle Genetics Announces Publication Of North American Subgroup Data From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the publication of data from the ECHELON-1 phase 3 clinical trial online in the journal Clinical Cancer Research.

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37 th Annual J.

Seattle Genetics And Takeda Present Positive Data From Phase 3 ECHELON-2 Clinical Trial For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics And Takeda Present Positive Data From Phase 3 ECHELON-2 Clinical Trial For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at the 60 th American Society of Hematology (ASH) Annual...

Seattle Genetics Highlights Additional Analyses From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At ASH Annual Meeting

Seattle Genetics Highlights Additional Analyses From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin ®, vinblastine and dacarbazine) in newly diagnosed stage III or IV...

Seattle Genetics Highlights Multiple Data Sets Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) At ASH Annual Meeting

Seattle Genetics Highlights Multiple Data Sets Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from three ongoing clinical trials evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) at the 60 th American Society of Hematology (ASH) Annual Meeting and...

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif.

Seattle Genetics Announces FDA Approval Of ADCETRIS® (Brentuximab Vedotin) In Combination With Chemotherapy For Adults With Previously Untreated Systemic Anaplastic Large Cell Lymphoma Or Other CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics Announces FDA Approval Of ADCETRIS® (Brentuximab Vedotin) In Combination With Chemotherapy For Adults With Previously Untreated Systemic Anaplastic Large Cell Lymphoma Or Other CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for ADCETRIS ® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.

FDA Grants Breakthrough Therapy Designation To ADCETRIS® (Brentuximab Vedotin) For Frontline Peripheral T-Cell Lymphomas

FDA Grants Breakthrough Therapy Designation To ADCETRIS® (Brentuximab Vedotin) For Frontline Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.

Seattle Genetics Initiates Phase 1 Clinical Trial Of SEA-BCMA For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics Initiates Phase 1 Clinical Trial Of SEA-BCMA For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

Seattle Genetics To Present At The Credit Suisse 27th Annual Healthcare Conference

Seattle Genetics To Present At The Credit Suisse 27th Annual Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.

Seattle Genetics Submits Supplemental Biologics License Application For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics Submits Supplemental Biologics License Application For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.

Seattle Genetics Announces More Than 30 Presentations At ASH 2018 Highlighting Progress With Broad ADCETRIS® (Brentuximab Vedotin) Development Program

Seattle Genetics Announces More Than 30 Presentations At ASH 2018 Highlighting Progress With Broad ADCETRIS® (Brentuximab Vedotin) Development Program

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 31 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation at the 60 th American Society of Hematology (ASH) Annual Meeting...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXS, EXPE, FNHC, SAVE Downgrades: BC, BLDR, CDE, CLB, CLS, CMG, COR, CRI, FBIZ, FBM, RXN, SGEN, THRM, TLRA, VC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) In Patients With Hodgkin Lymphoma At ISHL 2018

Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) In Patients With Hodgkin Lymphoma At ISHL 2018

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted multiple presentations evaluating ADCETRIS (brentuximab vedotin) across a broad range of Hodgkin lymphoma (HL) settings at the 11 th International Symposium on Hodgkin Lymphoma (ISHL) taking place in...

Seattle Genetics Reports Third Quarter 2018 Financial Results

Seattle Genetics Reports Third Quarter 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2018.

Genmab And Seattle Genetics Announce Tisotumab Vedotin Data To Be Presented At ESMO 2018 Congress

Genmab And Seattle Genetics Announce Tisotumab Vedotin Data To Be Presented At ESMO 2018 Congress

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that updated clinical data from the innovaTV 201 Phase II study evaluating tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer will be...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Third Quarter Financial Results On October 25, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of Third Quarter Financial Results On October 25, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets.

Seattle Genetics And Takeda Announce Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics And Takeda Announce Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited ( TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

TheStreet Quant Rating: C (Hold)